BioCryst Pharma (NASDAQ: BCRX) announced the presentation of trial results related to intravenous (I.V.) peramivir for the treatment of influenza ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE